Wire flash
FinanceVertex pays over 100% premium for Crinetics on promising CAH drug
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, paying a 102% premium. The deal was driven by Vertex's enthusiasm for Crinetics' experimental drug atumelnant, a once-daily pill for congenital adrenal hyperplasia (CAH) that showed strong clinical trial results. Vertex CEO Dr. Reshma Kewalramani stated the data was 'floored' and that the drug could transform CAH treatment. Vertex funded the acquisition with cash, avoiding debt. Despite the strategic rationale, Vertex shares fell from ~$530 to ~$485 following the announcement, reflecting investor apprehension about the high price. The article concludes that the acquisition could be a good long-term growth move for Vertex.
Source report
David Jagielski, CPA, The Motley Fool Published: July 14, 2026 at 12:20 PM UTC | 4 min read
- VRTX: -1.06%
- CRNX: +0.11%
- NVDA: -3.52%
When one company acquires another, a premium is common—especially if the target has strong fundamentals or promising assets. But paying double the current valuation is unusual.
That's exactly what Vertex Pharmaceuticals (NASDAQ: VRTX) did when it announced a $10 billion acquisition of Crinetics Pharmaceuticals (NASDAQ: CRNX), a company specializing in endocrine disorders and diseases. Vertex agreed to pay a 102% premium for the stock—slightly more than double its market value. While the deal delighted Crinetics investors, it did not sit well with Vertex shareholders, and the stock fell sharply on the news.
Management Was "Floored" by One Drug
Vertex expects the acquired assets to contribute as much as $5 billion in revenue. What particularly impressed management was a single drug candidate: atumelnant.
Although not yet approved, atumelnant has shown strong progress in clinical trials as a treatment for congenital adrenal hyperplasia (CAH). It is a once-daily pill that has been well-tolerated in trials, with no serious adverse events, and has helped bring patients' hormone levels back to near-normal ranges. If approved, it has the potential to become a leading therapy for CAH.
"When we saw that data, we were floored. That is very, very important to this field."
>
"We are also excited by the significant potential of atumelnant to transform the treatment landscape for CAH, setting a new standard of care where patients do not have to choose between managing their excess adrenal androgens and enduring the side effects of high-dose steroids."
>
— Dr. Reshma Kewalramani, Vertex CEO
Vertex Remains a Top Growth Stock to Own
The high price tag alarmed some investors. Prior to the announcement on July 6, Vertex shares were trading near their 52-week high at around $530. By the end of last week, the stock had fallen to just over $485.
While the sell-off was not severe, it reflects initial investor apprehension.
However, if management's assessment of the acquired drugs is correct—and they generate significant revenue and profit growth—buying Vertex stock today could prove to be a wise long-term move. Paying a premium for quality assets is sometimes necessary, and notably, Vertex funded the deal with cash, not debt.
Overall, the acquisition appears to be a low-risk, strategic move for Vertex, reinforcing its position as an excellent growth stock for long-term investors.
The Motley Fool has a disclosure policy.
Source
Yahoo FinanceWestern
Part of this Story
Vertex acquires Crinetics for $10B to expand into rare endocrine diseases